General Information
Drug ID
DR00304
Drug Name
Sorafenib
Synonyms
4(4-{3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide; 4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide; 4-(4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate; 4-(4-{3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide; 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide; 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide; 4-{4-[({[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]AMINO}CARBONYL)AMINO]PHENOXY}-N-METHYLPYRIDINE-2-CARBOXAMIDE; N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea; N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcar bamoyl)-4-pyridyloxy)phenyl)urea; N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea; Nexavar; Nexavar (TN); Sorafenib (INN); Sorafenib (Pan-TK inhibitor); Sorafenib [INN]; Sorafenibum
Drug Type
Small molecular drug
Indication Hepatocellular carcinoma [ICD11: 2C12.02] Approved [1]
Renal cell carcinoma [ICD11: 2C90] Approved [1]
Differentiated thyroid cancer [ICD11: 2D10] Approved [1]
Pancreatic cancer [ICD11: 2C10] Approved [1]
Therapeutic Class
Anticancer Agents
Structure
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=216239"></iframe>
3D MOL 2D MOL
Formula
C21H16ClF3N4O3
Canonical SMILES
CNC(=O)C1=NC=CC(=C1)OC2=CC=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F
InChI
InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)
InChIKey
MLDQJTXFUGDVEO-UHFFFAOYSA-N
CAS Number
CAS 284461-73-0
Pharmaceutical Properties Molecular Weight 464.829 Topological Polar Surface Area 92.4
Heavy Atom Count 32 Rotatable Bond Count 5
Hydrogen Bond Donor Count 3 Hydrogen Bond Acceptor Count 7
PubChem CID
216239
PubChem SID
103420820 , 103904444 , 104178872 , 113461200 , 117695450 , 117871124 , 12015507 , 124767621 , 124893320 , 124893321 , 124893322 , 124893323 , 124893324 , 125346960 , 14720365 , 14834034 , 30419984 , 46505329 , 46516901 , 50069824 , 50070560 , 50071324 , 50100118 , 50112741 , 53787819 , 53799234 , 56312334 , 56312336 , 56312338 , 56312517 , 56312519 , 56312521 , 56394953 , 57399755 , 68529952 , 74382940 , 75518900 , 7886069 , 81092852 , 833589 , 833590 , 85174603 , 85285882 , 85845166 , 91148447 , 92718861 , 93581025 , 9372814 , 96025209 , 99443909
ChEBI ID
ChEBI:50924
TTD Drug ID
D0W5HK
DT(s) Transporting This Drug BCRP Transporter Info Breast cancer resistance protein Substrate [2]
MRP2 Transporter Info Multidrug resistance-associated protein 2 Substrate [3]
OATP1B1 Transporter Info Organic anion transporting polypeptide 1B1 Substrate [4]
OATP1B3 Transporter Info Organic anion transporting polypeptide 1B3 Substrate [4]
P-GP Transporter Info P-glycoprotein 1 Substrate [5]
RALBP1 Transporter Info RalBP1-associated Eps domain-containing protein 2 Substrate [6]
Drug-Transporter Activity Data
Drug-Transporter Activity Data RALBP1 Transporter Info Km = 10.4 microM Human kidney cancer cells (Caki-2)-RALBP1 [6]
References
1 Sorafenib was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019)
2 Double-transduced MDCKII cells to study human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) interplay in drug transport across the blood-brain barrier. Mol Pharm. 2011 Apr 4;8(2):571-82.
3 Multidrug resistance protein 2 implicates anticancer drug-resistance to sorafenib. Biol Pharm Bull. 2011;34(3):433-5.
4 Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66.
5 Breast cancer resistance protein and P-glycoprotein limit sorafenib brain accumulation. Mol Cancer Ther. 2010 Feb;9(2):319-26.
6 Rlip76 transports sunitinib and sorafenib and mediates drug resistance in kidney cancer. Int J Cancer. 2010 Mar 15;126(6):1327-38.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.